Lowering Drug Costs for American Families Act
HB6166, titled the Lowering Drug Costs for American Families Act, would substantially expand federal prescription drug affordability rules across Medicare and private health coverage. The bill increases the number of drugs subject to Medicare drug price negotiation from 20 to 50, extends negotiated maximum fair prices to certain commercial-market enrollees through voluntary health plan participation, and requires plans that opt out to publicly disclose that choice. It also directs the Secretary to consider an average international market price benchmark when negotiating selected drugs, using prices from Australia, Canada, France, Germany, Japan, and the United Kingdom for negotiations beginning in 2028.
The bill further applies Medicare prescription drug inflation rebates to drugs furnished in the commercial market, including both Part B and Part D drugs, and adjusts the rebate calculations to account for billing units and other coverage sources such as Medicaid and 340B discounts. In addition, it creates new out-of-pocket protections in private insurance: annual overall cost-sharing caps, a separate annual prescription drug cost-sharing limit, and a specific insulin affordability rule that bars deductibles and limits cost-sharing for selected insulin products to the lesser of $35 per 30-day supply or 25 percent of the negotiated price. The bill also requires certain child-only coverage offerings and makes conforming changes to the Affordable Care Act, ERISA, and the Internal Revenue Code.
If enacted, the bill would amend the Social Security Act, the Public Health Service Act, ERISA, the Internal Revenue Code, and the Affordable Care Act to broaden federal control over prescription drug pricing and consumer cost-sharing. It would expand the Drug Price Negotiation Program, impose new disclosure and participation rules for group health plans and insurers, extend inflation rebate concepts into the commercial market, and establish new federal limits on out-of-pocket spending for prescription drugs and insulin in private coverage. The bill would directly affect Medicare, employer-sponsored plans, individual and small-group market coverage, insurers, pharmacy benefit managers, manufacturers, and beneficiaries/enrollees.
The bill’s stated purpose and structure indicate strong support for lowering drug costs, especially for families facing high prescription expenses and insulin costs. The absence of recorded committee transcripts or votes means there is no documented debate or roll-call sentiment in the provided materials, but the bill’s framing suggests a consumer-protection and affordability focus. Overall, the measure appears designed to appeal to supporters of stronger federal intervention in drug pricing and patient cost-sharing.
The main points of contention likely concern the bill’s expansion of federal pricing authority, its application of negotiated prices and inflation rebates into the commercial insurance market, and the new reporting and opt-out requirements for private plans. Insurers and employers may object to added administrative burden and limits on plan design, while drug manufacturers may oppose broader negotiation, international price benchmarking, and rebate expansion. Supporters are likely to emphasize lower patient costs, especially for insulin and high-cost specialty drugs, and broader access to affordable coverage.